ATE284872T1
(de)
*
|
2001-03-22 |
2005-01-15 |
Solvay Pharm Bv |
4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer wirkung
|
US20050054730A1
(en)
*
|
2001-03-27 |
2005-03-10 |
The Regents Of The University Of California |
Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
|
PL367814A1
(en)
|
2001-09-21 |
2005-03-07 |
Solvay Pharmaceuticals B.V. |
4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
|
UA78523C2
(en)
*
|
2001-09-21 |
2007-04-10 |
Solvay Pharm Bv |
4,5-dihydro-1h-pyrazoie derivatives as cb1 antagonists
|
TWI231757B
(en)
|
2001-09-21 |
2005-05-01 |
Solvay Pharm Bv |
1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
|
NZ534757A
(en)
|
2002-03-12 |
2006-07-28 |
Merck & Co Inc |
Substituted amides
|
US6825209B2
(en)
|
2002-04-15 |
2004-11-30 |
Research Triangle Institute |
Compounds having unique CB1 receptor binding selectivity and methods for their production and use
|
GB0216700D0
(en)
|
2002-07-18 |
2002-08-28 |
Astrazeneca Ab |
Process
|
RU2304580C2
(ru)
*
|
2002-07-29 |
2007-08-20 |
Ф.Хоффманн-Ля Рош Аг |
Новые бензодиоксолы
|
US7765162B2
(en)
*
|
2002-10-07 |
2010-07-27 |
Mastercard International Incorporated |
Method and system for conducting off-line and on-line pre-authorized payment transactions
|
JP2006506366A
(ja)
*
|
2002-10-18 |
2006-02-23 |
ファイザー・プロダクツ・インク |
カンナビノイド受容体リガンドおよびその使用方法
|
US7129239B2
(en)
*
|
2002-10-28 |
2006-10-31 |
Pfizer Inc. |
Purine compounds and uses thereof
|
US7247628B2
(en)
*
|
2002-12-12 |
2007-07-24 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
EP1583762B1
(en)
|
2003-01-02 |
2008-07-09 |
F. Hoffmann-La Roche Ag |
Pyrrolyl-thiazoles and their use as cb 1 receptor inverse agonists
|
US7294644B2
(en)
|
2003-01-02 |
2007-11-13 |
Hoffmann-La Roche Inc. |
CB 1 receptor inverse agonists
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
GB0302673D0
(en)
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
US7329658B2
(en)
*
|
2003-02-06 |
2008-02-12 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
US7176210B2
(en)
*
|
2003-02-10 |
2007-02-13 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
US7145012B2
(en)
|
2003-04-23 |
2006-12-05 |
Pfizer Inc. |
Cannabinoid receptor ligands and uses thereof
|
US7141669B2
(en)
*
|
2003-04-23 |
2006-11-28 |
Pfizer Inc. |
Cannabiniod receptor ligands and uses thereof
|
US7268133B2
(en)
*
|
2003-04-23 |
2007-09-11 |
Pfizer, Inc. Patent Department |
Cannabinoid receptor ligands and uses thereof
|
US20040214856A1
(en)
*
|
2003-04-23 |
2004-10-28 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
MXPA05011922A
(es)
*
|
2003-05-07 |
2006-02-17 |
Pfizer Prod Inc |
Ligandos del receptor de cannabinoides y sus usos.
|
US7232823B2
(en)
|
2003-06-09 |
2007-06-19 |
Pfizer, Inc. |
Cannabinoid receptor ligands and uses thereof
|
GB0314049D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
GB0314057D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
US20060135523A1
(en)
*
|
2003-06-18 |
2006-06-22 |
Astrazeneca Ab |
2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
|
US20040259887A1
(en)
*
|
2003-06-18 |
2004-12-23 |
Pfizer Inc |
Cannabinoid receptor ligands and uses thereof
|
GB0314261D0
(en)
*
|
2003-06-19 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
DE602004012858T2
(de)
|
2003-06-20 |
2009-05-14 |
F. Hoffmann-La Roche Ag |
2-aminobenzothiazole als cb1 rezeptor inverse agonisten
|
EP1663215A1
(en)
*
|
2003-09-02 |
2006-06-07 |
Solvay Pharmaceuticals GmbH |
Novel medical use of selective cb1- receptor antagonists
|
TW200511990A
(en)
*
|
2003-09-02 |
2005-04-01 |
Solvay Pharm Gmbh |
Novel medical uses of 4, 5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
|
US20050239859A2
(en)
*
|
2003-09-03 |
2005-10-27 |
Solvay Pharmaceuticals Gmbh |
Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
|
AR046132A1
(es)
*
|
2003-10-24 |
2005-11-23 |
Solvay Pharm Gmbh |
Composicin farmaceutica que contiene al menos un compuesto con actividad de receptor de cb1, o un profarmaco , tautomero o sal del mismo, como componente activo adecuado para el tratamiento y/o profilaxis de enfermedades relacionadas con el receptor cb1 en pacientes juveniles y/o para el tratamiento
|
US20050124660A1
(en)
*
|
2003-10-27 |
2005-06-09 |
Jochen Antel |
Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
|
US20050143441A1
(en)
*
|
2003-10-27 |
2005-06-30 |
Jochen Antel |
Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
|
GB0327331D0
(en)
*
|
2003-11-25 |
2003-12-31 |
Astrazeneca Ab |
Therapeutic agents
|
ATE384058T1
(de)
|
2003-12-08 |
2008-02-15 |
Hoffmann La Roche |
Thiazolderivate
|
JP4436369B2
(ja)
|
2004-01-28 |
2010-03-24 |
エフ.ホフマン−ラ ロシュ アーゲー |
スピロ−ベンゾジオキソール類およびそれらのcb1アンタゴニストとしての使用
|
US7745476B2
(en)
|
2004-01-30 |
2010-06-29 |
Solvay Pharmaceuticals B.V. |
1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
|
EP1713475B1
(en)
*
|
2004-01-30 |
2008-07-30 |
Solvay Pharmaceuticals B.V. |
1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
|
TW200533657A
(en)
|
2004-02-17 |
2005-10-16 |
Esteve Labor Dr |
Substituted pyrazoline compounds, their preparation and use as medicaments
|
GB0403780D0
(en)
*
|
2004-02-20 |
2004-03-24 |
Astrazeneca Ab |
Therapeutic agents
|
EP2305352A1
(en)
|
2004-04-02 |
2011-04-06 |
Merck Sharp & Dohme Corp. |
5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
|
CA2560417C
(en)
*
|
2004-04-03 |
2011-04-19 |
Astrazeneca Ab |
1,2-diarylimidazole-4-carboxamide derivatives
|
CN1950361A
(zh)
|
2004-05-10 |
2007-04-18 |
霍夫曼-拉罗奇有限公司 |
用于治疗肥胖的吡咯或咪唑酰胺化合物
|
ITMI20041032A1
(it)
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Compositi farmaceutici
|
ITMI20041033A1
(it)
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Composti farmaceutici
|
TW200602314A
(en)
|
2004-05-28 |
2006-01-16 |
Tanabe Seiyaku Co |
A novel pyrrolidine compound and a process for preparing the same
|
US20060025448A1
(en)
|
2004-07-22 |
2006-02-02 |
Cadila Healthcare Limited |
Hair growth stimulators
|
EP1807070A1
(en)
*
|
2004-09-29 |
2007-07-18 |
Schering Corporation |
Combinations of substituted azetidinones and cb1 antagonists
|
MX2007004889A
(es)
*
|
2004-10-25 |
2007-09-11 |
Solvay Pharm Gmbh |
Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados.
|
WO2006045478A1
(en)
|
2004-10-27 |
2006-05-04 |
F. Hoffmann-La Roche Ag |
New indole or benzimidazole derivatives
|
AU2005304039A1
(en)
|
2004-11-09 |
2006-05-18 |
F. Hoffmann-La Roche Ag |
Dibenzosuberone derivatives
|
WO2006060211A2
(en)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Pyrazole derivatives for the treatment of sexual dysfunction
|
WO2006060201A2
(en)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Pyrazole derivatives for the treatment of psychiatric disorders
|
WO2006060192A2
(en)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Pyrazole derivatives
|
WO2006060186A2
(en)
*
|
2004-11-30 |
2006-06-08 |
Bayer Pharmaceuticals Corporation |
Pyrazole derivatives for the treatment of dementia and related disorders
|
MX2007012213A
(es)
|
2005-04-06 |
2007-12-10 |
Hoffmann La Roche |
Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
|
CA2609783A1
(en)
*
|
2005-05-27 |
2006-12-07 |
Pfizer Products Inc. |
Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
|
PL1902034T3
(pl)
|
2005-06-02 |
2011-09-30 |
Glenmark Pharmaceuticals Sa |
Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania
|
US7923465B2
(en)
|
2005-06-02 |
2011-04-12 |
Glenmark Pharmaceuticals S.A. |
Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
EP1743890A1
(en)
*
|
2005-07-15 |
2007-01-17 |
Laboratorios Del Dr. Esteve, S.A. |
4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
|
WO2007009697A1
(en)
*
|
2005-07-15 |
2007-01-25 |
Laboratorios Del Dr. Esteve, S.A. |
Quaternary ammonium salts of substituted pyrazoline compounds, their preparation and use as medicaments
|
EP1749821A1
(en)
*
|
2005-07-15 |
2007-02-07 |
Laboratorios Del Dr. Esteve, S.A. |
Quaternary ammonium salts of substituted pyrazoline compounds, their preparation and use as medicaments
|
ES2330992B1
(es)
*
|
2005-07-15 |
2010-07-06 |
Laboratorios Del Dr. Esteve, S.A. |
Compuestos de pirazolina heterociclilsustituidos, su preparacion y uso como medicamentos.
|
WO2007009720A2
(en)
*
|
2005-07-15 |
2007-01-25 |
Laboratorios Del Dr. Esteve S.A. |
Prodrugs of pyrazoline compounds, their preparation and use as medicaments
|
EP1743892A1
(en)
|
2005-07-15 |
2007-01-17 |
Laboratorios del Dr. Esteve S.A. |
Substituted pyrazoline compounds, their preparation and use as medicaments
|
EP1749820A1
(en)
*
|
2005-07-15 |
2007-02-07 |
Laboratorios Del Dr. Esteve, S.A. |
Salts of substituted pyrazoline compounds, their preparation and use as medicaments
|
WO2007009704A2
(en)
*
|
2005-07-15 |
2007-01-25 |
Laboratorios Del Dr. Esteve, S.A. |
Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
|
EP1749526A1
(en)
*
|
2005-07-15 |
2007-02-07 |
Laboratorios Del Dr. Esteve, S.A. |
Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes
|
CA2619480A1
(en)
*
|
2005-08-17 |
2007-02-22 |
Solvay Pharmaceuticals Gmbh |
Method of using potassium channel inhibiting compounds
|
JP4658134B2
(ja)
|
2005-10-04 |
2011-03-23 |
田辺三菱製薬株式会社 |
光学活性4−ヒドロキシ−1,2,3,4−テトラヒドロキノリン化合物の製法
|
AR056560A1
(es)
|
2005-10-06 |
2007-10-10 |
Astrazeneca Ab |
Pirrolopiridinonas como moduladores cb1
|
EP1966146B1
(en)
*
|
2005-12-20 |
2011-03-02 |
Abbott Healthcare Products B.V. |
4,5-dihydro- (1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
|
WO2007125048A1
(en)
*
|
2006-04-27 |
2007-11-08 |
Solvay Pharmaceuticals Gmbh |
Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
|
US20070254863A1
(en)
*
|
2006-04-27 |
2007-11-01 |
Jochen Antel |
Use of CBx cannabinoid receptor modulators as potassium channel modulators
|
US7763607B2
(en)
|
2006-04-27 |
2010-07-27 |
Solvay Pharmaceuticals Gmbh |
Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
|
WO2007131219A2
(en)
|
2006-05-05 |
2007-11-15 |
Jenrin Discovery |
Cannabinoid receptor antagonists/inverse agonists
|
US7629346B2
(en)
|
2006-06-19 |
2009-12-08 |
Hoffmann-La Roche Inc. |
Pyrazinecarboxamide derivatives as CB1 antagonists
|
US7964728B2
(en)
*
|
2006-07-06 |
2011-06-21 |
Solvay Pharmaceuticals B.V. |
Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
|
AU2007283113A1
(en)
|
2006-08-08 |
2008-02-14 |
Sanofi-Aventis |
Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
|
US7781593B2
(en)
|
2006-09-14 |
2010-08-24 |
Hoffmann-La Roche Inc. |
5-phenyl-nicotinamide derivatives
|
SA07280510B1
(ar)
|
2006-09-22 |
2012-02-07 |
سولفاي فارماسوتيكالز بي . في |
سلفونيل بيرازول ومشتقات سلفونيل كربوكساميدين كمضادات ht6-5
|
AU2007336061B2
(en)
*
|
2006-12-18 |
2013-06-27 |
7Tm Pharma A/S |
CB1 receptor modulators
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US7655685B2
(en)
*
|
2007-11-02 |
2010-02-02 |
Jenrin Discovery, Inc. |
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
|
UY31968A
(es)
|
2008-07-09 |
2010-01-29 |
Sanofi Aventis |
Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
|
EP3241839B1
(en)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
EP2151234A1
(en)
*
|
2008-07-28 |
2010-02-10 |
Laboratorios Del. Dr. Esteve, S.A. |
Pharmaceutical formulation comprising a CB1-receptor compound in a solid solution and/or solid dispersion
|
AR072539A1
(es)
*
|
2008-08-01 |
2010-09-01 |
Solvay Pharm Bv |
Sintesis de derivados de 3,4-diaril -4,5-dihidro -(1h) - pirazol -1- carboxamida
|
CA2741125A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
WO2010051206A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
WO2010079241A1
(es)
|
2009-01-12 |
2010-07-15 |
Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion |
Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
|
CA2771278A1
(en)
|
2009-08-26 |
2011-03-03 |
Sanofi |
Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
|
WO2011044370A1
(en)
|
2009-10-07 |
2011-04-14 |
Jenrin Discovery |
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US8410107B2
(en)
|
2010-10-15 |
2013-04-02 |
Hoffmann-La Roche Inc. |
N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
|
AU2011329636B2
(en)
|
2010-11-18 |
2016-05-19 |
Jenrin Discovery |
Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
|
US8669254B2
(en)
|
2010-12-15 |
2014-03-11 |
Hoffman-La Roche Inc. |
Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
|
EP2677869B1
(en)
|
2011-02-25 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
WO2012120053A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120058A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
US8809325B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8809324B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2012120057A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
US8680131B2
(en)
|
2012-07-25 |
2014-03-25 |
Jenrin Discovery, Inc. |
Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers
|
AU2013296420B2
(en)
|
2012-08-01 |
2017-12-07 |
Lewis And Clark Pharmaceuticals, Inc. |
N-alkyl 2-(disubstituted)alkynyladenosine-5-uronamides as A2A agonists
|
AU2013296470B2
(en)
|
2012-08-02 |
2016-03-17 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2014078309A1
(en)
|
2012-11-13 |
2014-05-22 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Cannabinoid receptor mediating compounds
|
US11155521B2
(en)
|
2012-11-13 |
2021-10-26 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Cannabinoid receptor mediating compounds
|
AU2014219020A1
(en)
|
2013-02-22 |
2015-07-23 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
JP6606491B2
(ja)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
CA2948349C
(en)
*
|
2014-05-09 |
2023-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pyrazole derivatives and their use as cannabinoid receptor mediators
|
EP3109237A1
(en)
|
2015-06-22 |
2016-12-28 |
AnaMar AB |
Novel 5-ht2 antagonists
|
EP3551176A4
(en)
|
2016-12-06 |
2020-06-24 |
Merck Sharp & Dohme Corp. |
ANTIDIABETIC HETEROCYCLIC COMPOUNDS
|
EP4341246A1
(en)
|
2021-05-17 |
2024-03-27 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
A facile and odor-free approach to convert sulfonyl urea derivatives to chalcogenide sulfonyl urea derivatives
|